HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
50 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ITGB3
integrin subunit beta 3
Chromosome 17 · 17q21.32
NCBI Gene: 3690Ensembl: ENSG00000259207.10HGNC: HGNC:6156UniProt: P05106
1,223PubMed Papers
23Diseases
11Drugs
190Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneReceptor
RESEARCH IMPACT
Highly StudiedTrendingVariant-Rich
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
cell surfacefocal adhesionnegative chemotaxisplasma membraneGlanzmann thrombasthenia 1Glanzmann thrombastheniableeding disorder, platelet-type, 24autosomal dominant macrothrombocytopenia
✦AI Summary

ITGB3 (integrin subunit beta 3) is a cell adhesion molecule that mediates integrin-dependent cellular functions across multiple tissues. Structurally, ITGB3 functions as the β3 subunit of αIIbβ3 (fibrinogen receptor) and αvβ3 (vitronectin receptor) integrins, enabling cell-matrix and cell-cell adhesion 1. In trophoblast cells, ITGB3 promotes proliferation, migration, invasion, and adhesion while inhibiting apoptosis 2. Conversely, miRNA-103b-mediated downregulation of ITGB3 promotes apoptosis in stored platelets 3, and ITGB3 knockdown enhances radiosensitivity in osteosarcoma through JNK/c-JUN/RUNX2 pathway activation 4. Clinically, ITGB3 deficiency causes Glanzmann thrombasthenia, characterized by impaired platelet aggregation and mucocutaneous bleeding 1. In preeclampsia, reduced ITGB3 expression correlates with impaired trophoblast function 2. ITGB3 polymorphisms associate with schizophrenia age-at-onset 5 and autism through gene-gene interactions with SLC6A4 6. In focal segmental glomerulosclerosis, TSP-1/ITGB3 signaling mediates renal tubulointerstitial injury, blocked by cyclo-RGDfK 7. In osteosarcoma, ITGB3 promotes cisplatin resistance via MAPK and VEGF signaling pathways 8, positioning it as a therapeutic target.

Sources cited
1
miRNA-103b targets ITGB3 and promotes apoptosis in stored platelets
PMID: 34086556
2
ITGB3 is reduced in preeclampsia and enhances trophoblast cell proliferation, migration, invasion, and adhesion while inhibiting apoptosis
PMID: 39721996
3
ITGB3 polymorphisms show gene-gene interaction with SLC6A4 in autism with family history-dependent effects
PMID: 19588468
4
TSP-1/ITGB3 signaling mediates renal tubulointerstitial injury in FSGS, blockable by cyclo-RGDfK
PMID: 38960036
5
ITGB3 defects cause Glanzmann thrombasthenia with impaired platelet aggregation; β3 has wide tissue distribution affecting multiple organs
PMID: 21917754
6
ITGB3 polymorphisms associate with schizophrenia age-at-onset with functional conservation at disease-associated SNPs
PMID: 23860687
7
ITGB3 knockdown enhances osteosarcoma radiosensitivity through JNK/c-JUN/RUNX2 pathway activation and osteogenic differentiation
PMID: 40410897
8
ITGB3 promotes osteosarcoma cisplatin resistance through MAPK and VEGF signaling pathways
PMID: 36772869
Disease Associationsⓘ23
Glanzmann thrombasthenia 1Open Targets
0.82Strong
Glanzmann thrombastheniaOpen Targets
0.77Strong
bleeding disorder, platelet-type, 24Open Targets
0.70Strong
autosomal dominant macrothrombocytopeniaOpen Targets
0.64Moderate
cancerOpen Targets
0.62Moderate
myocardial infarctionOpen Targets
0.56Moderate
acute coronary syndromeOpen Targets
0.53Moderate
Noonan syndromeOpen Targets
0.53Moderate
hypertrophic cardiomyopathyOpen Targets
0.53Moderate
Costello syndromeOpen Targets
0.50Moderate
Recurrent thrombophlebitisOpen Targets
0.50Moderate
intermediate coronary syndromeOpen Targets
0.46Moderate
angina pectorisOpen Targets
0.39Weak
Ischemic strokeOpen Targets
0.39Weak
Abnormal bleedingOpen Targets
0.39Weak
hypothyroidismOpen Targets
0.38Weak
ThrombocytopeniaOpen Targets
0.38Weak
cardiofaciocutaneous syndromeOpen Targets
0.37Weak
strokeOpen Targets
0.36Weak
fetal and neonatal alloimmune thrombocytopeniaOpen Targets
0.35Weak
Bleeding disorder, platelet-type, 24UniProt
Fetomaternal alloimmune thrombocytopenia 1UniProt
Glanzmann thrombasthenia 2UniProt
Pathogenic Variants190
NM_000212.3(ITGB3):c.749A>G (p.Asp250Gly)Likely pathogenic
Prolonged bleeding time;Abnormal bleeding|Platelet-type bleeding disorder 16|Glanzmann thrombasthenia
★★★☆2025→ Residue 250
NM_000212.3(ITGB3):c.887_901del (p.Asp296_His300del)Likely pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 296
NM_000212.3(ITGB3):c.448A>G (p.Met150Val)Likely pathogenic
Glanzmann thrombasthenia|Glanzmann thrombasthenia 1|Glanzmann thrombasthenia 2|Bleeding disorder, platelet-type, 24|not provided
★★★☆2025→ Residue 150
NM_000212.3(ITGB3):c.856G>A (p.Gly286Arg)Pathogenic
Glanzmann thrombasthenia|not provided
★★★☆2025→ Residue 286
NM_000212.3(ITGB3):c.856G>C (p.Gly286Arg)Likely pathogenic
Abnormal bleeding|Glanzmann thrombasthenia
★★★☆2025→ Residue 286
NM_000212.3(ITGB3):c.567del (p.Tyr190fs)Likely pathogenic
Glanzmann thrombasthenia|not provided
★★★☆2025→ Residue 190
NM_000212.3(ITGB3):c.450G>A (p.Met150Ile)Likely pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 150
NM_000212.3(ITGB3):c.1595G>T (p.Cys532Phe)Likely pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 532
NM_000212.3(ITGB3):c.422A>G (p.Tyr141Cys)Pathogenic
Glanzmann thrombasthenia|not provided|Glanzmann thrombasthenia 2
★★★☆2025→ Residue 141
NM_000212.3(ITGB3):c.415G>C (p.Asp139His)Likely pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 139
NM_000212.3(ITGB3):c.2014+5G>ALikely pathogenic
Glanzmann thrombasthenia
★★★☆2025
NM_000212.3(ITGB3):c.1552C>T (p.Gln518Ter)Pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 518
NM_000212.3(ITGB3):c.1814G>A (p.Gly605Asp)Likely pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 605
NM_000212.3(ITGB3):c.1388G>C (p.Cys463Ser)Likely pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 463
NM_000212.3(ITGB3):c.1641C>G (p.Cys547Trp)Pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 547
NM_000212.3(ITGB3):c.2217del (p.Ile740fs)Likely pathogenic
Glanzmann thrombasthenia
★★★☆2025→ Residue 740
NM_000212.3(ITGB3):c.1639T>G (p.Cys547Gly)Pathogenic
Glanzmann thrombasthenia|not provided
★★★☆2025→ Residue 547
NM_000212.3(ITGB3):c.1813G>A (p.Gly605Ser)Likely pathogenic
Glanzmann thrombasthenia|not provided|Myocardial infarction, susceptibility to;Glanzmann thrombasthenia 2;Bleeding disorder, platelet-type, 24|Glanzmann thrombasthenia 2
★★★☆2025→ Residue 605
NM_000212.3(ITGB3):c.989T>A (p.Ile330Asn)Likely pathogenic
Glanzmann thrombasthenia
★★★☆2024→ Residue 330
NM_000212.3(ITGB3):c.917A>C (p.His306Pro)Likely pathogenic
Glanzmann thrombasthenia|not provided
★★★☆2024→ Residue 306
View on ClinVar ↗
Drug Targets11
ABCIXIMABApproved
Integrin alpha-IIb/beta-3 inhibitor
intermediate coronary syndrome
ABITUZUMABPhase II
Integrin alpha-V/beta-5 inhibitor
colorectal cancer
ATN-161Phase II
Integrin alpha-5/beta-1 antagonist
renal cell carcinoma
CILENGITIDEPhase III
Integrin alpha-V/beta-3 antagonist
rheumatoid arthritis
EPTIFIBATIDEApproved
Integrin alpha-IIb/beta-3 inhibitor
acute coronary syndrome
ETARACIZUMABPhase II
Integrin alpha-V/beta-3 antagonist
INTETUMUMABPhase II
Integrin alpha-V/beta-3 antagonist
prostate cancer
TADOCIZUMABPhase II
Integrin alpha-IIb/beta-3 antagonist
TIROFIBANApproved
Integrin alpha-IIb/beta-3 inhibitor
Recurrent thrombophlebitis
TIROFIBAN HYDROCHLORIDEApproved
Integrin alpha-IIb/beta-3 inhibitor
myocardial infarction
ZALUNFIBANPhase III
Integrin alpha-IIb/beta-3 inhibitor
ST Elevation Myocardial Infarction
Related Genes
CD9Protein interaction100%FGGProtein interaction100%TNCProtein interaction100%ITGAMProtein interaction100%ITGB2Protein interaction100%SELPProtein interaction100%
Tissue Expression6 tissues
Lung
100%
Heart
46%
Bone Marrow
39%
Liver
27%
Brain
25%
Ovary
15%
Gene Interaction Network
Click a node to explore
ITGB3CD9FGGTNCITGAMITGB2SELP
PROTEIN STRUCTURE
Preparing viewer…
PDB1MIZ · 1.90 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.69LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.54 [0.42–0.69]
RankingsWhere ITGB3 stands among ~20K protein-coding genes
  • #117of 20,598
    Most Researched1,223 · top 1%
  • #353of 1,025
    FDA-Approved Drug Targets4
  • #366of 5,498
    Most Pathogenic Variants190 · top 10%
  • #5,129of 17,882
    Most Constrained (LOEUF)0.69
Genes detectedITGB3
Sources retrieved50 papers
Response time—
📄 Sources
50▼
1
ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia.
PMID: 29125375
Platelets · 2018
1.00
2
MiRNA-103b Downregulates ITGB3 and Mediates Apoptosis in Ex Vivo Stored Human Platelets.
PMID: 34086556
Microrna · 2021
0.90
3
A STAT3/integrin axis accelerates pancreatic cancer initiation and progression.
PMID: 40701148
Cell Rep · 2025
0.86
4
Genetic association and gene-gene interaction analyses suggest likely involvement of ITGB3 and TPH2 with autism spectrum disorder (ASD) in the Indian population.
PMID: 23628433
Prog Neuropsychopharmacol Biol Psychiatry · 2013
0.82
5
Protecting the fetus from FNAIT.
PMID: 36394907
Blood · 2022
0.80